Abstract:BACKGROUND & AIMS: Chronic hepatitis B virus (HBV) infection is characterized by the presence of defective viral envelope proteins (hepatitis B surface antigen [HBsAg]) and the duration of infection- most patients acquire the infection at birth or during the first years of life. We investigated the effects of these factors on patients' lymphocyte and HBV-specific T-cell populations. METHODS: We collected blood samples and clinical data from 243 patients with HBV infection (3-75 years old) in the United Kingdom and China. We measured levels of HBV DNA, HBsAg, hepatitis B e antigen, and alanine aminotransferase; analyzed HBV genotypes; and isolated peripheral blood mononuclear cells (PBMCs). In PBMCs from 48 patients with varying levels of serum HBsAg, we measured 40 markers on nature killer and T cells by mass cytometry. PBMCs from 189 patients with chronic infection and 38 patients with resolved infections were incubated with HBV peptide libraries, and HBV-specific T cells were identified by interferon gamma enzyme-linked immune absorbent spot (ELISpot) assays or flow cytometry. We used multivariate linear regression and performed variable selection using the Akaike information criterion to identify covariates associated with HBV-specific responses of T cells. RESULTS: Although T- and natural killer cell phenotypes and functions did not change with level of serum HBsAg, numbers of HBs-specific T cells correlated with serum levels of HBsAg (r = 0.3367; P < .00001). After we performed the variable selection, the multivariate linear regression model identified patient age as the only factor significantly associated with numbers of HBs-specific T cells (P = .000115). In patients younger than 30 years, HBs-specific T cells constituted 28.26% of the total HBV-specific T cells; this value decreased to 7.14% in patients older than 30 years. CONCLUSIONS: In an analysis of immune cells from patients with chronic HBV infection, we found that the duration of HBsAg exposure, rather than the quantity of HBsAg, was associated with the level of anti-HBV immune response. Although the presence of HBs-specific T cells might not be required for the clearance of HBV infection in all patients, strategies to restore anti-HBV immune responses should be considered in patients younger than 30 years.

Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8+ T cell quality

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

Identification of the Association Between HBcAg-specific T Cell and Viral Control in Chronic HBV Infection Using a Cultured ELISPOT Assay.

Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels

The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection

Baseline Quantitative Hepatitis B Core Antibody Titre Alone Strongly Predicts HBeAg Seroconversion Across Chronic Hepatitis B Patients Treated with Peginterferon or Nucleos(t)ide Analogues.

Recovery of Circulating CD56dim NK Cells and the Balance of Th17/Treg after Nucleoside Analog Therapy in Patients with Chronic Hepatitis B and Low Levels of HBsAg

Clinical implications of hepatitis B virus core antigen‐mediated immunopathologic T cell responses in chronic hepatitis B

Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients with Chronic Hepatitis B Virus Infection

Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs

Hepatitis B e Antigen Induces NKG2A+ Natural Killer Cell Dysfunction via Regulatory T Cell-Derived Interleukin 10 in Chronic Hepatitis B Virus Infection

Primary analysis on the function of peripheral blood HBV-specific CD8 +T cells from patients with chronic hepatitis B

HBcAg-pulsed Dendritic Cell Vaccine Induces Th1 Polarization and Production of Hepatitis B Virus-Specific Cytotoxic T Lymphocytes.

TCRγδ(+)CD4(-)CD8(-) T Cells Suppress the CD8(+) T-cell Response to Hepatitis B Virus Peptides, and Are Associated with Viral Control in Chronic Hepatitis B.

Hepatitis B Surface Antigen Suppresses the Activation of Nuclear Factor Kappa B Pathway via Interaction With the TAK1-TAB2 Complex

Differential response of HBV Envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy

Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load

Combination of Pegylated Interferon-Alpha and Nucleos(t)ide Analogue Treatment Enhances the Activity of Natural Killer Cells in Nucleos(t)ide Analogue Experienced Chronic Hepatitis B Patients.

Quantitative Hepatitis B Core Antibody Levels in the Natural History of Hepatitis B Virus Infection.

Decreases in Activated CD8 + T Cells in Patients with Severe Hepatitis B Are Related to Outcomes

Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B